Screener
Beta Bionics BBNX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Beta Bionics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-323777
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,294 | 650 |
| Provision for expected credit losses | 16 | — |
| Stock-based compensation expense | 12,422 | 7,603 |
| Net provision (recovery) for excess and obsolete inventory | (179) | 347 |
| Change in fair value of warrant liabilities | — | 12,450 |
| Amortization of premium (discount) on short-term and long-term investments | 181 | (1,730) |
| Amortization of operating lease right-of-use asset | 811 | 607 |
Item 1. Financial Statements.
FAQ
- What is Beta Bionics's stock-based comp?
- Beta Bionics (BBNX) reported stock-based comp of $7.02M in Q2 2026.
- How has Beta Bionics's stock-based comp changed year-over-year?
- Beta Bionics's stock-based comp increased by 46.2% year-over-year, from $4.8M to $7.02M.
- What is the long-term trend for Beta Bionics's stock-based comp?
- Over 2 years (2023 to 2025), Beta Bionics's stock-based comp has grown at a 70.2% compound annual growth rate (CAGR), from $5.66M to $16.38M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Beta Bionics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude